
NMPA Accepts Snda For Ivonescimab In Combination With Chemotherapy As First-Line Treatment For Advanced Squamous Non-...
(MENAFN- PR Newswire) HONG KONG, July 28, 2025 /PRNewswire/ -- Akeso, Inc. (9926) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug …